Fig 2.

KIR3DL1 and HLA-B subtype combinations predict outcomes in patients with neuroblastoma (NB) who are treated with 3F8 on the basis of strength of interaction. Among patients with NB, 245 who received treatment with 3F8 were grouped according to expected strength of interaction of KIR3DL1 and HLA-B into strongly interacting pairs (blue lines), weakly interacting pairs (gray lines), and noninteracting pairs (gold lines). Kaplan-Meier curves for (A) overall survival and (B) progression-free survival are shown. HR, hazard ratio.